vs

Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $13.8M, roughly 1.6× CB Financial Services, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs -25.3%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-65.0M). Over the past eight quarters, CB Financial Services, Inc.'s revenue compounded faster (1.2% CAGR vs 0.4%).

CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

CBFV vs NKTR — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.6× larger
NKTR
$21.8M
$13.8M
CBFV
Growing faster (revenue YoY)
CBFV
CBFV
+45.1% gap
CBFV
19.9%
-25.3%
NKTR
More free cash flow
CBFV
CBFV
$82.1M more FCF
CBFV
$17.2M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
CBFV
CBFV
Annualised
CBFV
1.2%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBFV
CBFV
NKTR
NKTR
Revenue
$13.8M
$21.8M
Net Profit
$-36.1M
Gross Margin
Operating Margin
38.1%
-126.9%
Net Margin
-165.4%
Revenue YoY
19.9%
-25.3%
Net Profit YoY
-596.9%
EPS (diluted)
$0.90
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBFV
CBFV
NKTR
NKTR
Q4 25
$13.8M
$21.8M
Q3 25
$2.4M
$11.8M
Q2 25
$13.5M
$11.2M
Q1 25
$12.1M
$10.5M
Q4 24
$13.2M
$29.2M
Q3 24
$12.7M
$24.1M
Q2 24
$12.2M
$23.5M
Q1 24
$13.5M
$21.6M
Net Profit
CBFV
CBFV
NKTR
NKTR
Q4 25
$-36.1M
Q3 25
$-5.7M
$-35.5M
Q2 25
$3.9M
$-41.6M
Q1 25
$1.9M
$-50.9M
Q4 24
$7.3M
Q3 24
$3.2M
$-37.1M
Q2 24
$2.6M
$-52.4M
Q1 24
$4.2M
$-36.8M
Gross Margin
CBFV
CBFV
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
CBFV
CBFV
NKTR
NKTR
Q4 25
38.1%
-126.9%
Q3 25
-289.8%
-268.6%
Q2 25
35.0%
-324.2%
Q1 25
19.3%
-425.8%
Q4 24
23.1%
49.2%
Q3 24
31.2%
-142.4%
Q2 24
26.4%
-211.9%
Q1 24
37.9%
-163.7%
Net Margin
CBFV
CBFV
NKTR
NKTR
Q4 25
-165.4%
Q3 25
-235.2%
-301.3%
Q2 25
29.3%
-372.2%
Q1 25
15.8%
-486.4%
Q4 24
24.9%
Q3 24
25.3%
-153.6%
Q2 24
21.8%
-222.9%
Q1 24
31.1%
-170.1%
EPS (diluted)
CBFV
CBFV
NKTR
NKTR
Q4 25
$0.90
$-4.67
Q3 25
$-1.07
$-1.87
Q2 25
$0.74
$-2.95
Q1 25
$0.35
$-0.24
Q4 24
$0.45
$-2.07
Q3 24
$0.60
$-2.66
Q2 24
$0.51
$-3.76
Q1 24
$0.82
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBFV
CBFV
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$31.7M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$157.5M
$89.8M
Total Assets
$1.5B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBFV
CBFV
NKTR
NKTR
Q4 25
$31.7M
$15.1M
Q3 25
$55.9M
$41.0M
Q2 25
$64.5M
$43.0M
Q1 25
$61.3M
$38.9M
Q4 24
$49.6M
$44.3M
Q3 24
$147.3M
$30.1M
Q2 24
$142.6M
$27.9M
Q1 24
$73.7M
$48.6M
Stockholders' Equity
CBFV
CBFV
NKTR
NKTR
Q4 25
$157.5M
$89.8M
Q3 25
$152.5M
$85.1M
Q2 25
$148.4M
$-24.2M
Q1 25
$148.3M
$13.7M
Q4 24
$147.4M
$60.7M
Q3 24
$149.1M
$48.9M
Q2 24
$142.9M
$79.7M
Q1 24
$141.6M
$126.7M
Total Assets
CBFV
CBFV
NKTR
NKTR
Q4 25
$1.5B
$280.4M
Q3 25
$1.5B
$301.3M
Q2 25
$1.5B
$207.5M
Q1 25
$1.5B
$256.2M
Q4 24
$1.5B
$303.9M
Q3 24
$1.6B
$308.0M
Q2 24
$1.6B
$343.3M
Q1 24
$1.5B
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBFV
CBFV
NKTR
NKTR
Operating Cash FlowLast quarter
$17.8M
$-65.0M
Free Cash FlowOCF − Capex
$17.2M
$-65.0M
FCF MarginFCF / Revenue
124.1%
-298.0%
Capex IntensityCapex / Revenue
4.7%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.5M
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBFV
CBFV
NKTR
NKTR
Q4 25
$17.8M
$-65.0M
Q3 25
$4.6M
$-48.8M
Q2 25
$4.1M
$-45.7M
Q1 25
$4.0M
$-49.1M
Q4 24
$6.8M
$-46.2M
Q3 24
$3.1M
$-43.9M
Q2 24
$-1.2M
$-37.7M
Q1 24
$3.3M
$-47.9M
Free Cash Flow
CBFV
CBFV
NKTR
NKTR
Q4 25
$17.2M
$-65.0M
Q3 25
$4.5M
$-48.9M
Q2 25
$3.9M
$-45.8M
Q1 25
$3.9M
$-49.1M
Q4 24
$3.4M
$-46.6M
Q3 24
$2.2M
$-44.6M
Q2 24
$-2.4M
$-37.9M
Q1 24
$2.3M
$-48.0M
FCF Margin
CBFV
CBFV
NKTR
NKTR
Q4 25
124.1%
-298.0%
Q3 25
186.5%
-414.5%
Q2 25
28.8%
-409.6%
Q1 25
32.5%
-469.0%
Q4 24
26.0%
-159.9%
Q3 24
17.4%
-184.9%
Q2 24
-19.6%
-161.3%
Q1 24
17.0%
-222.0%
Capex Intensity
CBFV
CBFV
NKTR
NKTR
Q4 25
4.7%
0.1%
Q3 25
4.3%
1.0%
Q2 25
1.9%
0.3%
Q1 25
0.8%
0.0%
Q4 24
25.1%
1.6%
Q3 24
6.7%
2.8%
Q2 24
10.0%
0.8%
Q1 24
7.2%
0.7%
Cash Conversion
CBFV
CBFV
NKTR
NKTR
Q4 25
Q3 25
Q2 25
1.05×
Q1 25
2.11×
Q4 24
-6.36×
Q3 24
0.95×
Q2 24
-0.44×
Q1 24
0.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons